University of Texas's MD Anderson Cancer Center: Ribociclib Added to Endocrine Therapy Extends Survival in Postmenopausal Patients With Metastatic Breast Cancer
March 10, 2022
March 10, 2022
HOUSTON, Texas, March 10 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on March 9, 2022:
* * *
Longest reported overall survival benefit with a first-line CDK4/6 inhibitor in breast cancer
* * *
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients w . . .
* * *
Longest reported overall survival benefit with a first-line CDK4/6 inhibitor in breast cancer
* * *
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients w . . .